About Us
Committed to Improving Patients’ Life
Harbour BioMed is a global, clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in the areas of oncology and immunological diseases to address unmet patient’s needs.
We are building a robust pipeline with our integrated Harbour antibody platform, that enable us to develop highly differentiated antibodies against various disease targets with great potency and safety profiles. Our proprietary Harbour Mice® generate fully human monoclonal antibodies in the classical two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon our HCAb antibodies, the HCAb-based immune cell engagers (HBICETM) are capable of delivering tumor killing effects unachievable by combination therapies. Integrated with our single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.
Innovative Medicines for Healthy Life.
To Become the Leading Company Driving Global Innovation of NextGen Antibody Therapeutics.
HBM’s efforts are driven by our vision of delivering “Innovative Medicines for Healthy Life”. To realize this vision, we have been partnering with global academic institutions, biotechnology and pharmaceutical companies by leveraging our platforms. We have established a strong track record of portfolio includes strategically selected co-development clinical assets and internal innovative NextGen projects to address unmet patient’s need. We also provide technology licensing for our proprietary Harbour antibody technologies to accelerate the industry innovation on antibody therapeutics.
Our strategic priorities are focused on driving global inventions of transformative next generation medicines powered by our proprietary technology platforms and data driven science.
Immunotherapies have been increasingly recognized as critical components of evolving treatment paradigms owing to the superior efficacy and safety profiles. However, the current standards of care in oncology and immunological diseases fall short owing to complexities of these multicomponent, multifactorial diseases, thereby limiting the response and outcomes in most patient populations.
With a strong patient-centric approach, we combine the power of Harbour Mice® with other advanced technologies, like single B cell cloning, bispecific antibody, bioinformatics and translational research to generate and identify lead antibody candidates to treat diseases. Our highly efficient antibody discovery engine ensures sustainable innovation in order to develop a diversified and balanced pipeline of potentially first-in-class and/or best-in-class cutting-edge immunology and IO therapies, both independently, and through collaborations with global pharmaceutical and research institutions. Our HCAb and HBICETM platforms allow us to design unique and novel formats of antibodies, including bi- and multi-specific antibodies, that aim to exponentially enhance the clinical efficacy and safety of these candidates which are unachievable by combination therapies. We aspire to lead the next wave of immunotherapies in oncology and immunology.
Our portfolio also consists of strategically selected, in-licensed and risk-mitigated clinical assets with near-term revenue potential targeting diseases with high unmet need. Batoclimab (HBM9161) and tanfanercept (HBM9036) are the two anchor assets in this portfolio, and both of them are well positioned as the first mover to address significant unmet needs in their respective addressable markets in China.
The human tumor microenvironment is a unique bionetwork of heterogeneous collection of tumor cells along with different kind of immune cells, myeloid cells, lymphocytes, and a repertoire of signaling molecules. Approaches so far resulting into standard of care have met with limited success owing to several different factors including, but not limited to, access to the TME, heterogeneity of mechanisms involved with tumors, amongst others. Through rigorous biomarker analyses and artificial intelligence (machine learning) we aim to identify and establish the right immunotherapy for the right patient populations that would boost treatment outcomes. Targeting the immune cell engager pathways our HBICE approach is directed towards combining early and late stage immune engagers to prime and target the tumors for immediate and complete elimination. With a multi-pronged antibody (HBICE) approach to identify novel targets and mechanisms with in the TME, our goal is to transform cancer treatment paradigm by enabling the body’s own immune system to attack these tumors and bring long-term benefits to patients.
We focus on niche conditions with high unmet medical needs where a unique antibody approach combined with new or known targets may offer a meaningful therapeutic solution with a long-lasting impact for patients suffering from these conditions.
Harbour BioMed Raises $102.8M in Series C Financing to Accelerate Development of Its Innovative Portfolio of Next Generation Biologics
Utrecht University, Erasmus Medical Center and Harbour BioMed Researchers Report Discovery of Antibody that Blocks Novel Coronavirus SARS-CoV-2 Infection in Cells
Harbour BioMed Raises $75 Million Series B2 Venture Capital Financing to Accelerate Its Innovative Pipeline
Mount Sinai and Harbour BioMed Collaborate to Advance Novel Biotherapies for the Treatment of Cancer and Coronavirus COVID-19
Harbour BioMed Announces U.S. FDA Approval of IND for Its Next Generation anti-CTLA-4 Antibody, HBM4003, to Treat Cancer
Harbour BioMed Announces Completion of Phase 1 Study in China of HBM9161, an Anti-FcRn Antibody
Harbour BioMed Announces Completion of Phase 2 Study of HBM9036 in Patients with Moderate-to-Severe Dry Eye Disease in China
Yinuoke and Harbour BioMed Announce A Strategic Alliance to Develop Innovative Biologics to Address Unmet Patients' Needs
Harbour BioMed and Chia Tai Tianqing Pharmaceutical Group Ltd. Announce Strategic Alliance to Discover, Develop and Commercialize Innovative Biologics
Harbour BioMed integrates the Beacon® Platform to Accelerate Antibody Discovery
Harbour BioMed Receives Approval to Start the Phase II Clinical Trial of Its Innovative Drug Candidate for The Treatment of Inflammatory Eye Disease
Harbour BioMed Raises $85 Million in Series B Financing to Accelerate Its Innovative Pipeline
Harbour BioMed and Glenmark Pharmaceuticals Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers
Harbour BioMed Completes Series A3 Round Financing to Accelerate the Development of Clinical Programs and Company Growth
Harbour BioMed Established
MD, PhD
Founder, Chairman and Chief Executive Officer
Chief Development Officer
PhD, MBA
Chief Strategy Officer & Head, US Operations
PhD, MBA
Chief Commercial Officer
Senior Vice President, Head of Technology Platform
Ph.D.
Head of Discovery Biology
Vice President, Head of Finance and Investor Relations